In the first half of the year, the fund's top 30 stocks were 90% heavy-stock pharmaceutical stocks

With the end of the first half of the year, the performance of public funds also surfaced. The stock market was sharply adjusted in the first half of the year, with more than 10 industry indices falling by more than 20% and public funds underperforming overall. Statistics show that in the first half of the volatile decline, equity funds fell by an average of nearly 12%, mixed funds fell by an average of nearly 5%. It is worth noting that the performance of pharmaceutical-themed funds is eye-catching, in the top 30 active management funds, there are 27 funds re-positioned pharmaceutical stocks.equity funds fell an average of 11.89 per cent
From the overall performance of public funds, Wind News statistics show that equity funds fell an average of 11.89 per cent in the first half of this year;
specifically, of the 2,624 actively managed funds established before 2018, only 577 have achieved positive returns, of which only 100 have yields of more than 5 per cent and 40 have yields of more than 10 per cent. Of the 2029 funds that fell in the first half of the year, 1,375, or more than 50 per cent, fell by more than 5 per cent, while 55 fell by more than 20 per cent.
In terms of the performance of actively managed funds, Wells Fargo Precision Medicine, China Central Europe Healthcare C and Wells Fargo New Power A were in the top three, with first-half returns of 29.52%, 24.09% and 23.85%, respectively, and the last three declines were 32.07%, 31.09% and 27.9%, respectively.
among the top funds, medical-themed funds led the first half of the public fund performance list. In the top 30, in addition to BOC Alpha, BOC Advantage Industry, Noan Lixin, China Post enjoy a year-long regular and rich countries new power A and rich countries new power C, the rest of the funds are all medical theme funds, it is worth proposing that the rich countries new power A, rich countries new power C and Noanlixin are all full of pharmaceutical stocks. In other words, 27 of the top 30 actively managed funds in the first half of the year have re-positioned pharmaceutical stocks.
In the first half of this year's weak market, although Shenwan Pharmaceutical Bio-Level Index rose only 3.11%, but the performance of leading stocks eye-catching, Hengrui Pharmaceuticals, East China Medicine, Chipping , Zhifei Bio, Kantai Biologicals, Changchun High-tech, Tonghua Dongbao and other stock prices rose to a new high, in the "leading for the United States" market, for the public fund to contribute a lot of income.The performance of the two fund managers was eye-catching
in the first half of this year, the market as a whole fell, with only leisure services, pharmaceuticals, biology and food and beverage rising among the 28 first-tier sectors, while 20 sectors fell by more than 15%, with 11 industry indices such as communications, electrical equipment, machinery and equipment, non-ferrous metals, construction decoration and electronics falling by more than 20%. Public funds, by contrast, outperformed major market indices.
Galaxy Securities Fund Research Center believes that in the first half of this year, public funds by embracing the certainty and stability of high pharmaceutical biology, food and beverage and household appliances and other sectors, to resist the market's sharp adjustment, the overall decline significantly better than the market average decline.
from a fund manager's point of view, Wells Fargo's Yu Yang was the biggest winner in the first half. Public data show that since August 2011, Yu Yang has served as a pharmaceutical industry analyst at First Securities, Huatron Securities and Anxin Securities, joined the Wells Fargo Fund in November 2015 and served as a Wells Fargo New Power Fund Manager, served as Wells Fargo Precision Medical Fund Manager on November 17, 2017 and Wells Fargo Healthcare Fund Manager on February 8, 2018, with all of the funds under its management re-positioning pharmaceutical stocks, with first-half returns of more than 21%. From its fund manager for more than half a year, seized the pharmaceutical leading stocks accelerated the rise period.
, the fund manager of the Bank of China, performed eye-catchingly. The BOC Alpha Fund, which is managed by ITC, returned 14.97 per cent in the first half of the year, while the BOC Advantage Industry Fund returned 14.59 per cent, and the BOC Sustained Growth Theme Fund, established on January 12 this year, has returned 9.13 per cent since its inception. According to the data, Mr. Ho has been a fund manager for BOC Advantage since July 9, 2015 and a BOC Alpha Fund Manager since September 16, 2015, with positive returns in any year under his management. According to the Fund's 2018 quarterly report, among the top ten heavy stocks under its management, there is no pharmaceutical stock in the first half of the year against the trend of the upswing of the United States, Asia Photoelectrectr, New Classic, China Testing and So on. (Shanghai Securities News)